Skip to main content

Fiscal Wizard · Single-issue tearsheet

SANA / Jun 20, 2026 Run #7192

SANA

Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Composite verdict

F 15.9 / 100
Bearish setup · Mean Reversion 8 drivers · 6 gates blocking
  • Connors RSI(2)
  • MA Rejection
  • Double 7s
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 338th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 14 signals100% Bear
Momentum Bearish 14Mean-reversion Bearish 37

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

31.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
P/B 75
Free Cash Flow Yield 0
EPS Growth (YoY) 69
Greenblatt ROC 10
Return on Equity 25

Technicals Bearish

0.1 / 100

Bearish setup leads (Connors RSI(2), MA Rejection, Double 7s); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Connors RSI(2) 12
MA Rejection 16
Double 7s 17

Risk Gates

6 blocking 2 caution

6 guards active, 26 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SANA.